# A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

> **NCT02094417** · PHASE2 · COMPLETED · sponsor: **Kyowa Kirin Korea Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** AMG531

## Key facts

- **NCT ID:** NCT02094417
- **Lead sponsor:** Kyowa Kirin Korea Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-14
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-11-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094417, "A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02094417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*